New data from the SELECT trial confirms semaglutide reduces major cardiovascular events by 20% independent of baseline body weight or how much weight patients actually lose, reshaping how clinicians think about GLP-1 therapy.
A pivotal prespecified analysis of the SELECT trial published in Nature Medicine has deepened understanding of semaglutide's cardioprotective effects. The analysis found that semaglutide's 20% reduction in major adverse cardiovascular events (MACE) � heart attacks, strokes, and cardiovascular death � was largely independent of baseline adiposity measures and the magnitude of weight loss achieved during the trial. Patients who lost minimal weight still experienced meaningful cardiovascular protection.
This finding has significant implications for how GLP-1 receptor agonists are classified. Researchers are now calling for semaglutide to be reconceptualized as a disease-modifying cardiovascular therapy rather than simply an anti-obesity medication. The direct cardioprotective mechanisms under investigation include anti-inflammatory effects on atherosclerotic plaques, improved endothelial function, and reduced visceral adipose tissue inflammation independent of total fat mass changes.
A separate 2026 analysis examined semaglutide's effects on liver fibrosis in SELECT participants with established cardiovascular disease. Results showed significant reductions in liver fibrosis markers and improved hepatic outcomes, adding NASH (non-alcoholic steatohepatitis) to the expanding list of semaglutide's benefits. This is particularly relevant given that NASH affects an estimated 6�8% of the global adult population and has no approved treatments beyond GLP-1 agonists.
The FDA has responded to this accumulating evidence by expanding prescribing guidelines for GLP-1 medications. As the SELECT trial continues its long-term follow-up and oral semaglutide gains traction following its approval for weight management, semaglutide's story continues to evolve from diabetes drug to broad-spectrum metabolic and cardiovascular protector.
Source: Nature Medicine
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.